A Multicenter, Randomized, Double-blind, Placebo Parallel-controlled, Phase I/II Study to Explore Safety and Efficacy of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis Suppurativa
Latest Information Update: 31 Mar 2024
At a glance
- Drugs BDB 001 Beijing Defengrei Biotechnology (Primary)
- Indications Hidradenitis suppurativa
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Staidson Beijing BioPharmaceuticals
- 26 Jun 2023 Status changed from recruiting to completed.
- 16 Apr 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jun 2023.
- 18 May 2022 Planned number of patients changed from 30 to 49.